Atara Biotherapeutics stock popped nearly 5 percent Dec. 9 on promising safety and efficacy data for its flagship drug tab-cel. In a study of 61 patients with disorders related to Epstein Barr Virus, the drug had high overall response and survival rates, Atara said in a news release. The Thousand Oaks company is working to…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
